WO2011118810A1 - 栄養組成物 - Google Patents
栄養組成物 Download PDFInfo
- Publication number
- WO2011118810A1 WO2011118810A1 PCT/JP2011/057453 JP2011057453W WO2011118810A1 WO 2011118810 A1 WO2011118810 A1 WO 2011118810A1 JP 2011057453 W JP2011057453 W JP 2011057453W WO 2011118810 A1 WO2011118810 A1 WO 2011118810A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nutritional composition
- composition according
- fatty acid
- nutritional
- lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/10—Foods or foodstuffs containing additives; Preparation or treatment thereof containing emulsifiers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
Definitions
- the present invention relates to a nutritional composition containing, as a main component, a lipid which is a calorie element capable of supplying a high calorie. More specifically, the present invention relates to a nutritional composition that has excellent emulsification stability, is suitable for both oral intake and tube administration, and can be provided as a pharmaceutical or a food or drink.
- the composition of the nutritional composition is made higher than the conventional preparation and the dosage of the preparation is made small. Conceivable. By making the concentration high, a sufficient amount of calorie is contained, and by making the volume small, the burden on the patient and caregivers can be reduced.
- concentration as a general nutrition composition, that is, a preparation containing proteins, carbohydrates, lipids, minerals, and vitamins, from the viewpoint of formulation and ingredient stability, It can be said that it is preferable to use a replenisher-like form mainly containing lipids and specialized for calorific element replenishment.
- Microlipid (“Microlipid”; Novartis, registered trademark) is commercially available as such a fat emulsion for oral and enteral nutrition aimed at supplementing calorie with a high concentration and a small volume.
- This is a 100% fat composition of safflower oil, and it is a liquid emulsion formulation of 4.5 kcal / mL (50 g lipid / 100 mL lipid) in a glass bottle sealed with a screw cap, with a capacity of 89 mL / piece It is.
- the emulsified preparation is a preferred liquid composition for caloric supplementation, but the fatty acid composition is not particularly considered, and it cannot be said that the utilization efficiency as a caloric element is good.
- Patent Documents 1 and 2 As a fat emulsion that can be easily used for tube administration, a technique (Patent Documents 1 and 2) is disclosed in which a prefilled syringe preparation that substantially avoids contact between the liquid surface and oxygen is disclosed.
- these techniques only provide formulation techniques suitable for intravenous administration, and no mention is made of application to gastric or enteral nutrition. Also, the disclosed filling capacity is several mL, which has not been thoroughly examined from the viewpoint of replenishment of calorie.
- Pharmaceutical formulations such as Intralipid (Termo Co., Ltd., registered trademark) and Intralipos (Otsuka Pharmaceutical Factory, registered trademark), which are commercially available fat emulsions, are also intended for intravenous administration.
- the lipid content is 10% or 20%, and it is mainly composed of long-chain fatty acids. From the viewpoint of “a preparation containing a high concentration of lipid”, it is an ideal transgastric Or it cannot be said to be an enteral nutritional product.
- Patent Documents 3 to 5 are disclosed as techniques relating to the preparation of fat emulsion.
- these are techniques disclosed mainly for the stability of the formulation, especially the effect of suppressing the phase separation by controlling the particle size, and no consideration has been given to the lipid concentration from the viewpoint of caloric administration. It does not disclose a more preferable technique regarding nutrient administration.
- glucose and glycerin are blended as an emulsion stabilizer, and there is a risk that diarrhea becomes a problem during oral and enteral administration depending on the blending amount and the condition of the recipient. Therefore, information disclosure is insufficient as a technique for performing ideal gastric or enteral nutrition.
- the fat emulsion is assumed to be administered intravenously, in order to avoid clogging of the filter during administration, in order to reduce the average particle size of the emulsified particles, high-pressure or multiple emulsification treatments are performed during production. is necessary.
- Patent Documents 6 to 8 are disclosed as techniques relating to a kit for a liquid nutritional composition. These technologies are characterized by manufacturing and storing each nutrient separately, but they are not kits focused on calorimetric supplementation, but can be administered in a small volume and high concentration, especially calorie Improvement of utilization efficiency of elementary lipids has not been studied. Further, in such a kit, it is necessary to mix a plurality of liquid agents in use, but this operation may be complicated.
- an object of the present invention is to provide a nutritional composition containing a high concentration of lipid, which is a calorie that supplies a high calorie, and suitable for both oral intake and tube administration such as gastric or enteral administration.
- An object of the present invention is to provide a nutritional composition having excellent emulsification stability and excellent utilization efficiency as a calorimetric element.
- the present inventors use a lipid containing a predetermined amount of medium-chain fatty acid, and use an emulsifier having a fatty acid in its structure, such as lecithin and organic acid monoglyceride, as an emulsifier.
- an emulsifier having a fatty acid in its structure such as lecithin and organic acid monoglyceride
- An oil-in-water emulsion composition comprising a lipid having a medium chain fatty acid content of 20 wt% to 80 wt% in the lipid and an emulsifier having a fatty acid in its structure, A nutritional composition, wherein the total content of the emulsifier is 25 (w / v)% to 65 (w / v)% based on the total amount of the composition.
- the nutritional composition according to [1], wherein the emulsifier having a fatty acid in its structure is one or more selected from the group consisting of lecithin and organic acid monoglycerides.
- the nutritional composition according to the above [9] which is for patients with kidney disease.
- [12] The nutritional composition according to [1] or [2] above, wherein a volume of 10 mL to 100 mL is used as one packaging unit. [13] The nutritional composition according to [1] or [2], which is filled in a sterile state. [14] The nutritional composition according to [1] or [2], which is for oral consumption. [15] The nutritional composition according to the above [1] or [2], which is for gastric or enteral administration. [16] A pharmaceutical comprising the nutritional composition according to any one of [1] to [11] above. [17] A food or drink containing the nutritional composition according to any one of [1] to [11]. [18] A nutritional kit for oral intake or for gastric or enteral administration, comprising a comprehensive nutritional composition and the nutritional composition according to any one of [1] to [10] above.
- the nutritional composition of the present invention has excellent emulsification stability, and when stored for a long period of time, changes in the emulsified state such as water separation and phase separation such as creaming are not observed for at least one month.
- changes in the emulsified state such as water separation and phase separation such as creaming are not observed for at least one month.
- it since it can be made into a small volume while containing a high concentration of lipid that is highly efficient as a calorie, it is suitable for both oral intake, gastric or enteral administration such as enteral administration, and heat supply Useful for patients who need it.
- the nutritional composition of the present invention is an oil-in-water emulsified composition containing a high concentration of lipid having a high medium chain fatty acid content and emulsified with an emulsifier having a fatty acid in its structure, such as lecithin and organic acid monoglyceride.
- the “lipid” contained in the nutritional composition of the present invention refers to fat used as a calorie, that is, fats and oils.
- fats and oils can be used without particular limitation as long as they are provided for pharmaceuticals or foods and drinks.
- Vegetable oils such as coconut oil and lettuce oil
- animal oils such as fish oil, chicken oil, beef tallow, pork tallow and sheep fat
- milk fats such as butter oil, butter and margarine and processed fats and oils.
- one or more of these are selected and used.
- the “medium chain fatty acid” means a fatty acid having 8 to 12 carbon atoms such as caprylic acid, capric acid, lauric acid, etc., and these are preferably contained in the form of medium chain fatty acid triglyceride in the lipid.
- Medium-chain fatty acids are generally about 4 times faster in digestion and absorption than long-chain fatty acids present in fats and oils, and after absorption, they are transported to the liver via the portal vein without passing through the lymph vessels, and are rapidly metabolized. Therefore, it can be suitably used as a calorimetric element.
- the content of the medium chain fatty acid in the lipid is less than 20% by weight because the utilization efficiency as a calorimetric element is not sufficient. On the other hand, if it exceeds 80% by weight, there is a risk of developing acidosis accompanying an increase in blood ketone bodies.
- “Coconard MT”, “Coconard RK”, “Coconard ML” (manufactured by Kao Chemical), “Derios SJ”, “Derios VJ” (manufactured by Cognis), “Actor M-1”, “ Products commercially available as “medium chain fatty acid triglycerides” such as Actor M-107FR (manufactured by Riken Vitamin Co., Ltd.) can be used.
- coconut oil, palm oil, etc. those extracted and purified from natural plants such as coconut may be used, but it is convenient to use commercially available products.
- an emulsifier having a fatty acid in its structure is used.
- Fatty acids contained in the structure of the emulsifier include fatty acids derived from vegetable oils and fats such as coconut oil, palm oil, soybean oil, and rapeseed oil, particularly 12 to 18 carbon atoms such as lauric acid, myristic acid, palmitic acid, and stearic acid. Examples thereof include unsaturated fatty acids having about 18 carbon atoms such as about saturated fatty acids, oleic acid, linoleic acid, and linolenic acid.
- emulsifier examples include glycerin fatty acid ester (fatty acid monoglyceride, fatty acid diglyceride), organic acid monoglyceride which is a derivative of the glycerin fatty acid ester, polyglycerin fatty acid ester, polyglycerin condensed ricinoleic acid ester, sorbitan fatty acid ester, sucrose fatty acid ester, lecithin Etc., and one or more of these can be selected and used.
- glycerin fatty acid ester fatty acid monoglyceride, fatty acid diglyceride
- organic acid monoglyceride which is a derivative of the glycerin fatty acid ester
- polyglycerin fatty acid ester polyglycerin condensed ricinoleic acid ester
- sorbitan fatty acid ester sucrose fatty acid ester
- lecithin Etc. lecithin Etc.
- a composition that has excellent emulsion stability and does not cause separation of an aqueous phase and an oil phase for at least one month during storage. Obtainable.
- Lecithin refers to a lipid product containing phospholipid, but as lecithin that can be used as an emulsifier in the present invention, soy lecithin obtained from soybean and mainly composed of phosphatidylcholine; plant lecithin obtained from seeds such as rape; egg yolk Egg yolk lecithin obtained by enzymatic degradation of soybean lecithin, plant lecithin or egg yolk lecithin, and enzymatic degradation lecithin mainly composed of phosphatidic acid and / or lysolecithin; mainly sphingomyelin, phosphatidylinositol, phosphatidylethanolamine and phosphatidylcholine Fractionated lecithin as component; partial hydrolyzed lecithin obtained by partially hydrolyzing lecithin, hydrogenated lecithin obtained by hydrogenating lecithin, hydroxylated lecithin obtained by introducing hydroxyl group into lecithin, etc.
- the organic acid monoglyceride is a derivative of the monoglyceride in which an organic acid is bonded to the remaining hydroxyl group of the fatty acid monoglyceride.
- examples of the organic acid monoglyceride that can be used as an emulsifier in the present invention include acetic acid monoglyceride, citric acid monoglyceride, succinic acid monoglyceride, diacetyltartaric acid monoglyceride, and lactic acid monoglyceride.
- citric acid monoglyceride is most preferably used since it is excellent in acid-resistant emulsification and is also used as an auxiliary for fat and oil antioxidants.
- one or more fatty acid glycerin esters particularly preferably fatty acid monoglycerides, and one or more selected from the group consisting of lecithin and organic acid monoglycerides are used in combination. Emulsification stability is obtained.
- the total amount of the emulsifier having a fatty acid in the structure thereof is 5% by weight to 40% by weight, preferably 10% by weight with respect to the total amount of lipid used. % To 30 wt.
- one or more selected from the group consisting of lecithin and organic acid monoglyceride is 2 (w / v)% to 26 (w / v)% of the total amount of these, It is preferably contained in an amount of 30 to 100% by weight based on the total amount of the emulsifier having a fatty acid in the structure.
- the total content of the lipid and the emulsifier having a fatty acid in its structure is 25 (w / v)% to 65 (w / v)% with respect to the total amount of the composition. 25 (w / v)% to 55 (w / v)%, preferably 30 (w / v)% to 50 (w / v)%.
- emulsifiers that do not contain fatty acids in the structure, and other raw materials that have an emulsion stabilizing action, such as gelling agents such as agar and carrageenan, thickening polysaccharides; chelating action such as phosphates and citrates Salts and the like may be used.
- gelling agents such as agar and carrageenan, thickening polysaccharides
- chelating action such as phosphates and citrates Salts and the like
- one or more kinds can be selected, and the blending amount and blending ratio can be determined.
- one or two or more selected from the group consisting of carbohydrates and glycerin have problems with digestive disorders (such as diarrhea) caused by elevated blood glucose levels or high osmotic pressure. If it does not become a grade, it can be contained.
- the nutritional composition of the present invention contains lipids at a high concentration, the water content is relatively reduced by further containing a large amount of carbohydrates and the like, and the sterilization is caused by a decrease in production suitability, flavor, and viscosity. And convenience during administration may be impaired.
- the carbohydrate when one or more selected from the group consisting of carbohydrate and glycerin is contained, it is 35 (w / v)% or less, preferably 10 (w / v) based on the total amount of the composition. v) It should be less than%.
- the carbohydrate is not necessarily contained. If it is in a situation where carbohydrates are supplied into the recipient's body as a separate nutritional composition including intravenous nutrition, blood sugar levels can be controlled by using a composition that does not contain carbohydrates. It becomes possible. That is, by considering the saccharide content, it can be an appropriate calorie supplement source for diabetic patients.
- lung diseases such as chronic obstructive respiratory disease, it is possible to reduce the generation of metabolic carbon dioxide by administration of carbohydrates, and to reduce the ventilation load on the lungs. Have.
- Sugars that can be used in the present invention include monosaccharides such as glucose and fructose; disaccharides such as sucrose and maltose; oligosaccharides such as fructooligosaccharides, galactooligosaccharides, mannan oligosaccharides, and dairy oligosaccharides; dextrin, dextran, Examples thereof include polysaccharides such as starch and glycogen; sugar alcohols such as xylitol, sorbitol and reduced dextrin.
- the weight ratio of omega-3 fatty acids to omega-6 fatty acids in the lipid is preferably 1:10 to 10: 1, and 1: 4 to 4: 1. More preferably.
- “ ⁇ -3 fatty acid” is also expressed as “n-3 fatty acid”, and examples include ⁇ -linolenic acid, eicosapentaenoic acid, docosapentaenoic acid, and docosahexaenoic acid. Since eicosapentaenoic acid is known to have an effect of improving insulin resistance, it can be more suitably used in the case of diabetic nephropathy. In the present invention, one or more of these are selected and used.
- ⁇ -6 fatty acid is also expressed as “n-6 fatty acid”, and examples thereof include linoleic acid, ⁇ -linolenic acid, arachidonic acid and the like. In the present invention, one or more of these are selected and used.
- the ⁇ -3 fatty acid is abundant in perilla oil, linseed oil, fish oil, etc.
- the ⁇ -6 fatty acid is abundant in safflower oil, sunflower oil, soybean oil, rapeseed oil, evening primrose oil, etc. Can be extracted and purified from these oils and fats.
- what was manufactured by the chemical synthesis method, the fermentation method, etc. can also be used, and the commercial item marketed for food-drinks can also be used.
- the fats and oils rich in ⁇ -3 fatty acids or ⁇ -6 fatty acids can be used as they are as a lipid source.
- the above fatty acid composition can be achieved by using an emulsifier having such a ⁇ -3 fatty acid or ⁇ -6 fatty acid in its structure.
- the omega-3 fatty acid contains either or both of eicosapentaenoic acid and docosahexaenoic acid from the viewpoint of the effect on various inflammatory diseases.
- the weight ratio of omega-3 fatty acid to omega-6 fatty acid the nutritional state of the patient expected to be used, and the amount of essential fatty acid contained in the composition when other nutritional compositions are used together, nutritional composition It is determined in consideration of the administration route of the product, the price and grade of the oil and fat.
- a nutritional composition capable of appropriate nutritional management can be provided as a nutritional supplement preparation for patients with kidney disease by adjusting the phosphorus content.
- the phosphorus content is preferably 20 mg or less per 100 kcal of the nutritional composition, more preferably 10 mg or less.
- the compounding amount of phosphorus it is necessary to adjust the compounding amount of the phosphorus source components such as phosphates and phosphates, and appropriately use the amount of lecithin and lysolecithin used as emulsifiers. It is necessary to specify.
- organic acid monoglyceride instead of phospholipid.
- proteins can be added as other calorimetric elements.
- protein include casein and its salts, milk protein such as whey, soy protein, wheat protein, corn protein, potato protein, fish meat protein, animal meat protein, egg protein and the like. Those processed into flakes or pellets can also be used. These hydrolysates can also be used, and one or more of them may be selected from amino acids and salts thereof. Moreover, these can also be mix
- nutritional components can be added to the nutritional composition of the present invention.
- Such nutritional components include dietary fiber, vitamins and minerals.
- dietary fiber examples include pectin, agarose, glucomannan, cellulose, indigestible dextrin, and the like, and one or more of these can be selected and used.
- the dietary fiber preferably has an energy conversion factor other than 0 kcal / g as indicated by the Ministry of Health, Labor and Welfare notification (Shokushin No. 0217001, Shokushin No. 0217002).
- Examples of such dietary fiber include guar gum and its hydrolyzate, indigestible dextrin, wheat germ, and water-soluble soybean dietary fiber.
- vitamin A such as retinol, retinal, retinoic acid; carotenoid such as ⁇ -carotene; vitamin D such as ergocalciferol and cholecalciferol; vitamin E such as ⁇ -tocopherol and ⁇ -tocopherol; phylloquinone, menaquinone
- vitamin K such as vitamin K
- vitamin B 1 such as thiamine
- vitamin B 2 such as riboflavin
- vitamin B 6 such as pyridoxine, pyridoxal, pyridoxamine
- vitamin B 12 such as cyanocobalamin, nicotinic acid, nicotinamide, etc.
- vitamin B groups such as niacin, pantothenic acid, biotin, and folic acid
- water-soluble vitamins such as vitamin C.
- Examples of minerals include common minerals such as sodium, potassium, magnesium, calcium, phosphorus, iodine, iron, copper, manganese, selenium, zinc, chromium and molybdenum.
- the phosphorus content per 100 kcal of nutrition composition shall be 20 mg or less.
- the nutritional composition of the present invention preferably has a high calorific value and a small volume within the range where there is no problem in the stability of the composition, and specifically 2.5 kcal / mL to 6 kcal / mL. It is preferably 3 kcal / mL to 5 kcal / mL.
- additives can be added to the nutritional composition of the present invention as necessary.
- examples of such additives include pH adjusters such as citric acid, sodium citrate, acetic acid, sodium acetate, gluconic acid, sodium hydroxide; antioxidants such as erythorbic acid, butylhydroxyanisole, propyl gallate; aspartame, liquorice extract , Saccharin, etc .; acidulants such as lactic acid, succinic acid, tartaric acid, malic acid; sodium benzoate, sodium edetate, sorbic acid, sodium sorbate, methyl parahydroxybenzoate, butyl paraoxybenzoate, etc.
- Colorants such as Bengala, yellow iron oxide, black iron oxide, carmine, edible blue No. 1, edible yellow No. 4, edible red No. 2 and the like.
- the nutritional composition of the present invention can be provided as a pharmaceutical or a food or drink as it is or with a carrier for a pharmaceutical or a food or drink.
- the pharmaceutical can be a preparation for oral intake or a preparation for tube administration such as a gastric and enteral nutrient.
- the food and drink may be a milky or creamy general food, but is preferably a health food such as a food for specified health use, a nutritional functional food, a nutritional supplement, or other health food.
- the content of one or more selected from the group consisting of carbohydrates and glycerin is 35 (w / v)% or less with respect to the total amount of the composition.
- the composition controlled to become it can be set as the pharmaceutical or food-drinks for diabetics.
- it can be set as the pharmaceutical or food-drinks for patients with a kidney disease by using the composition which controlled phosphorus content to 20 mg or less per 100 kcal of nutritional composition.
- the capacity of the nutritional composition of the present invention per package should be small as long as there is no hindrance in replenishing the necessary amount of heat from the viewpoints of consumption per use, suppression of microbial contamination, handling, etc. Is preferred.
- preferably 10 mL to 100 mL, more preferably 10 mL to 50 mL is used as one packaging unit.
- one package unit is the above-mentioned volume, when the whole amount is administered by tube at one time, there is almost no need to pay attention to the injection rate, and it is easy to supply sufficient calorie.
- Tube feeding via gastrostomy and intestinal fistula is rapidly spreading, because it is easier than conventional nasogastric feeding and can improve the quality of life for patients. It is said that there is.
- the nutritional composition of the present invention is used for gastrostomy or enteral fistula administration, the time required for administration is expected to be several minutes, and while administering the necessary calorie according to the patient's condition, while watching the state The implementation time can be shortened. In addition, it is hygienic and has little waste, and the administration operation is simpler, which may further improve the quality of life.
- the osmotic pressure can be easily adjusted, the risk of diarrhea can be reduced. Furthermore, in elderly people, the stomach is often shrinking with age, and the amount of food that can be consumed is extremely small, so the nutritional composition of the present invention containing a small amount of high-concentration lipids Is useful. It is more effective especially when gastroesophageal reflux occurs frequently or when the gastric volume is reduced and the administration volume is limited.
- the pH of the nutritional composition of the present invention is preferably 5 to 7.5, and 5.5 to 6.8. More preferably. By adjusting the pH to near neutrality, it is possible to reduce the occurrence of side effects even when used for patients with gastric wall disorders.
- a container filled with a small-volume nutritional composition it is used via a tube administration tube such as a tube for enteral stomach or enteral nutrition, and has a portion that can be connected to the tube and can be injected at the same time.
- a container having a mechanism capable of flushing the inside of the tube with air, water, or gel is preferable.
- it is not used directly through a tube tube because it has such a form and the content liquid is kept sterile, for example, it is used by adding the nutritional composition of the present invention to a comprehensive nutrient liquid food Even when the nutritional composition of the present invention is used as a kit preparation, microbial contamination can be avoided as much as possible.
- Specific examples of such containers include disposable containers such as prefilled syringes, drop-shaped containers made by blow molding or multilayer film, and pouches with stoppers.
- the material of the container such as a prefilled syringe may be either glass or plastic, but is preferably plastic from the viewpoint of safety during transportation and use and waste disposal. Moreover, transparency, light-shielding property and heat resistance are favorable, and those that can be recycled and are stable with respect to the filler are more preferable.
- Plastic resins include polysulfone resin, polyethersulfone resin, polyamide resin, polycarbonate resin, polyvinyl chloride resin, acrylic resin, cyclic polyolefin resin, cyclic polyolefin copolymer resin, polymethylpentene resin, polyester resin, polypropylene resin, polyethylene Examples thereof include resins and resins made of a crosslinked polymer such as polyethylene terephthalate resin.
- an elastic polymer material such as rubber or elastomer can be used for the gasket portion, but rubber having good sliding property coated with silicone or fluororesin is preferable.
- the portion connected to the tube for tube administration should be tapered so as to be gradually reduced in diameter from the tip so as to adapt to various shapes. It is maintained by making it a shape that can be opened by closing the plug, fitting with a screw cap and a spout shape, and cutting off a part of the connecting portion.
- sterile means that no microorganism is present in the substance, and in the case of a pharmaceutical preparation, it means that the conditions prescribed by the Japanese Pharmacopoeia are satisfied.
- food and drink there are no food poisoning bacteria, infectious disease pathogens, or microorganisms that cause spoilage, and so-called retort foods that do not contain microorganisms that cause infection, spoilage, or economic loss under normal temperature distribution.
- retort foods that do not contain microorganisms that cause infection, spoilage, or economic loss under normal temperature distribution.
- Such sterilization is achieved by aseptic filling or high-temperature high-pressure sterilization after filling.
- sterility is maintained until immediately before use, and microbial contamination may occur by filling a container suitable for connection with a tube tube, administration of the composition, and washing of the tube tube. Is extremely reduced, and it becomes possible to administer easily.
- the nutritional composition of the present invention can be provided in combination with other nutritional compositions as a nutritional kit for oral intake or for tube administration such as gastric or enteral administration.
- a comprehensive nutrition composition such as a comprehensive nutrition liquid food
- a higher calorie can be supplied. Since the nutritional composition of the present invention has a small volume while containing a high concentration of lipid, the increase in volume with respect to the heat supply amount is kept to a minimum amount. Therefore, it is more effective when the volume of the composition to be administered is limited.
- the nutritional composition of the present invention efficiently supplies heat by using a composition in which the amount of carbohydrate added is considered. In addition, the risk of fluctuations in blood glucose level is low, and patient nutrition management is facilitated.
- the nutritional composition according to the present invention can be obtained by preparing an oil-in-water emulsion composition by a normal emulsification method. For example, when adding a water-soluble component, heat the aqueous phase in which the component is mixed with water, and when adding a lipid and an emulsifier, and further adding an oil-soluble component, add the mixed oil-phase component.
- the mixture can be prepared by mixing and homogenizing using a homomixer, a colloid mill, a high-pressure homogenizer, a microfluidizer, or the like.
- the emulsifier can be added to the aqueous phase.
- a thermally unstable component like some vitamins etc., it can add and mix, after emulsifying and cooling.
- the particle size of the emulsion particles of the obtained nutritional composition can be measured by a general particle size measurement method for emulsions and micelles, for example, dynamic light scattering method, laser diffraction method and the like. About the nutritional composition which concerns on this invention, the average particle diameter was measured using the laser diffraction scattering method.
- the nutritional composition of the present invention After preparing the nutritional composition of the present invention, it is filled in a container such as the syringe or pouch described above and sterilized.
- the sterilization method is selected in consideration of the components contained in the nutritional composition and the heat and pressure stability of the container to be filled.
- the high-pressure steam sterilization method, filter filtration method, gas sterilization method using ethylene oxide gas, etc. Etc. can be used. It is also preferable to aseptically fill the nutritional composition by acceptive filling.
- Example 1 Nutritional composition (1) According to the composition shown in Table 1, 740 g of prepared water was weighed in a 3 L stainless steel bucket (hereinafter referred to as A) and heated to 70 ° C to 80 ° C in a hot water bath. Subsequently, dextrin was added and dissolved under high-speed stirring conditions of 3000 rpm with TK Robotics (manufactured by PRIMIX Corporation). (2) Soybean oil and medium chain fatty acid triglyceride as edible fats and oils, powdered lecithin (enzymatically decomposed lecithin) and fatty acid monoglyceride as emulsifiers were added to A.
- A 3 L stainless steel bucket
- the volume was increased to 2000 mL, and then dissolved and dispersed until a uniform state was obtained, and then treated twice with a high-pressure homogenizer at a homogeneous pressure of 70 MPa.
- An aluminum pouch was filled so that the weight per piece was 150 g, and a retort sterilization treatment was performed at 123 ° C. for 10 minutes to obtain a nutritional composition.
- the above composition was stored at 25 ° C., and the day after sterilization, the rotor No. was measured with a rotary viscometer (“BH-80”, manufactured by Toki Sangyo Co., Ltd.). It was about 300 cP when measured at 25 ° C. under conditions of 1, 12 rpm. Moreover, it was 0.19 micrometer when the average particle diameter was measured using the laser diffraction scattering method particle size distribution measuring apparatus (LS13 ⁇ 320; Beckman Coulter company make). The pH was 5.8.
- Example 2 Nutritional composition (1) According to the composition shown in Table 1, 740 g of prepared water was weighed in a 3 L stainless steel bucket (hereinafter referred to as B), and heated to 70 to 80 ° C in a hot water bath. Subsequently, dextrin was added and dissolved under high-speed stirring conditions of 3000 rpm with TK Robotics (manufactured by PRIMIX Corporation). (2) Soybean oil and medium chain fatty acid triglyceride as edible fats and oils, powdered lecithin (enzymatically decomposed lecithin), citric acid monoglyceride and fatty acid monoglyceride as B were added to B.
- B 3 L stainless steel bucket
- the above composition was stored at 25 ° C., and the day after sterilization, the rotor No. was measured with a rotary viscometer (“BH-80”, manufactured by Toki Sangyo Co., Ltd.). It was about 180 cP when measured at 25 ° C. under conditions of 1, 12 rpm. Moreover, it was 0.19 micrometer when the average particle diameter was measured using the laser diffraction scattering method particle size distribution measuring apparatus (LS13 ⁇ 320; Beckman Coulter company make). The pH was 4.0.
- Example 1 the calculated value of the phosphorus content per 100 kcal and the calorie
- Example 3 Nutritional composition (1) In accordance with the composition shown in Table 2, 900 g of prepared water was weighed in a 3 L stainless steel bucket (hereinafter referred to as C) and heated to 70 ° C to 80 ° C in a hot water bath. (2) Powder lecithin (enzymatically decomposed lecithin), which is an emulsifier, was added to C under high-speed stirring conditions at 3000 rpm using TK Robotics (manufactured by PRIMIX Corporation).
- C 3 L stainless steel bucket
- TK Robotics manufactured by PRIMIX Corporation
- soybean oil which is an edible oil and fat, medium chain fatty acid triglyceride, rapeseed oil and refined fish oil, and pasty lecithin (soybean lecithin) and fatty acid monoglyceride, which are emulsifiers, were mixed in advance and then added to C.
- the volume was increased to 2000 mL, and then dissolved and dispersed until a uniform state was obtained, and then treated twice with a high-pressure homogenizer at a homogeneous pressure of 70 MPa.
- An aluminum pouch was filled so that the weight per piece became 150 g, and retort sterilization treatment was performed at 123 ° C. for 10 minutes.
- the above composition was stored at 25 ° C., and the day after sterilization, the rotor No. was measured with a rotary viscometer (“BH-80”, manufactured by Toki Sangyo Co., Ltd.). It was about 30 cP when measured at 25 ° C. under conditions of 1, 12 rpm. Moreover, it was 0.29 micrometer when the average particle diameter was measured using the laser diffraction scattering method particle size distribution measuring apparatus (LS13 * 320; Beckman Coulter company make). The pH was 6.0.
- Nutritional composition (1) According to the composition shown in Table 2, 900 g of the prepared water was weighed in a 3 L stainless steel bucket (hereinafter referred to as D) and heated to 70 ° C to 80 ° C in a hot water bath. (2) Powder lecithin, which is an emulsifier (enzymatically decomposed lecithin), was added to D under high-speed stirring conditions at 3000 rpm using TK Robotics (manufactured by PRIMIX Corporation).
- D 3 L stainless steel bucket
- TK Robotics manufactured by PRIMIX Corporation
- soybean oil which is an edible fat, medium chain fatty acid triglyceride, rapeseed oil and refined fish oil, and pasty lecithin (soybean lecithin), which are emulsifiers, citric acid monoglyceride and fatty acid monoglyceride were mixed in advance and then added to D.
- the volume was increased to 2000 mL, and then dissolved and dispersed until a uniform state was obtained, and then treated twice with a high-pressure homogenizer at a homogeneous pressure of 70 MPa.
- An aluminum pouch was filled so that the weight per piece became 150 g, and retort sterilization treatment was performed at 123 ° C. for 10 minutes.
- the above composition was stored at 25 ° C., and the day after sterilization, the rotor No. was measured with a rotary viscometer (“BH-80”, manufactured by Toki Sangyo Co., Ltd.). It was about 16 cP when measured at 25 ° C. under conditions of 1, 12 rpm. Moreover, it was 0.20 micrometer when the average particle diameter was measured using the laser diffraction scattering method particle size distribution measuring apparatus (LS13 * 320; Beckman Coulter company make). The pH was 4.3.
- Example 3 the calculated value of the phosphorus content per 100 kcal and the calorie
- lipids that are excellent in emulsion stability and have high utilization efficiency as a calorie can be contained at a high concentration and can be made into a small volume.
- a nutritional composition suitable for any tube administration such as enteral administration can be provided. Therefore, the nutritional composition is useful for patients who need a calorie supply.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pediatric Medicine (AREA)
- Medicinal Preparation (AREA)
- Animal Behavior & Ethology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
[1]脂質中の中鎖脂肪酸含有量が20重量%~80重量%である脂質と、その構造中に脂肪酸を有する乳化剤を含有してなる水中油型乳化組成物であって、前記脂質および前記乳化剤の総含有量が、組成物全量に対して25(w/v)%~65(w/v)%である、栄養組成物。
[2]その構造中に脂肪酸を有する乳化剤が、レシチンおよび有機酸モノグリセリドよりなる群から選択した1種または2種以上である、上記[1]に記載の栄養組成物。
[3]有機酸モノグリセリドがクエン酸モノグリセリドである、上記[2]に記載の栄養組成物。
[4]脂質中の中鎖脂肪酸が、中鎖脂肪酸トリグリセリドの形態で含有されている、上記[1]または[2]に記載の栄養組成物。
[5]さらに、糖類およびグリセリンよりなる群から選択した1種または2種以上を含有する、上記[1]または[2]に記載の栄養組成物。
[6]糖類およびグリセリンよりなる群から選択した1種または2種以上の含有量が、組成物全量に対して35(w/v)%以下である、上記[5]に記載の栄養組成物。
[7]糖尿病患者用である、上記[6]に記載の栄養組成物。
[8]脂質中のω-3系脂肪酸とω-6系脂肪酸の重量比が1:10~10:1である脂質を含有する、上記[1]または[2]に記載の栄養組成物。
[9]リンの含有量が、栄養組成物100kcalあたり20mg以下である、上記[1]または[2]に記載の栄養組成物。
[10]腎臓病患者用である、上記[9]に記載の栄養組成物。
[11]さらに、タンパク質、食物繊維、ビタミン類およびミネラル類よりなる群から選択される1種または2種以上を含有する、上記[1]または[2]に記載の栄養組成物。
[12]10mL~100mLの容量を一包装単位とする、上記[1]または[2]に記載の栄養組成物。
[13]無菌状態で充填されている、上記[1]または[2]に記載の栄養組成物。
[14]経口摂取用である、上記[1]または[2]に記載の栄養組成物。
[15]経胃または経腸投与用である、上記[1]または[2]に記載の栄養組成物。
[16]上記[1]~[11]のいずれかに記載の栄養組成物を含有する医薬品。
[17]上記[1]~[11]のいずれかに記載の栄養組成物を含有する飲食品。
[18]総合栄養組成物と、上記[1]~[10]のいずれかに記載の栄養組成物とを含む、経口摂取用または経胃もしくは経腸投与用栄養剤キット。
(1)表1に示す組成に従い、3Lのステンレスバケツ(以下Aと記す)に調合水740gを計量し、湯浴にて70℃~80℃に加温した。次いで、TKロボミックス(プライミクス株式会社製)にて、3000rpmの高速攪拌条件下に、デキストリンを添加し、溶解した。
(2)食用油脂である大豆油および中鎖脂肪酸トリグリセリド、ならびに乳化剤である粉末レシチン(酵素分解レシチン)および脂肪酸モノグリセリドをAに投入した。次いで2000mLにメスアップした後、均一な状態となるまで溶解分散させ、高圧ホモジナイザーにより70MPaの均質圧で2回処理した。
(3)アルミパウチに1個あたりの重量が150gとなるように充填し、123℃で10分間レトルト滅菌処理を行い、栄養組成物を得た。
(1)表1に示す組成に従い、3Lのステンレスバケツ(以下Bと記す)に調合水740gを計量し、湯浴にて70℃~80℃に加温した。次いで、TKロボミックス(プライミクス株式会社製)にて、3000rpmの高速攪拌条件下に、デキストリンを添加し、溶解した。
(2)食用油脂である大豆油および中鎖脂肪酸トリグリセリド、ならびに乳化剤である粉末レシチン(酵素分解レシチン)、クエン酸モノグリセリドおよび脂肪酸モノグリセリドをBに投入した。次いで2000mLにメスアップした後、均一な状態となるまで溶解分散させ、高圧ホモジナイザーにより70MPaの均質圧で2回処理した。
(3)アルミパウチに1個あたりの重量が150gとなるよう充填し、123℃で10分間レトルト滅菌処理を行った。
(1)表2に示す組成に従い、3Lのステンレスバケツ(以下Cと記す)に調合水900gを計量し、湯浴にて70℃~80℃に加温した。
(2)TKロボミックス(プライミクス株式会社製)にて、3000rpmの高速攪拌条件下に、乳化剤である粉末レシチン(酵素分解レシチン)をCに投入した。また、食用油脂である大豆油、中鎖脂肪酸トリグリセリド、ナタネ油および精製魚油、ならびに乳化剤であるペースト状レシチン(大豆レシチン)および脂肪酸モノグリセリドを、あらかじめ混合した後、Cに投入した。なお、各種食用油脂の配合量は、脂質組成において、ω-3系脂肪酸:ω-6系脂肪酸=1:2.7(重量比)となるように調整した。次いで2000mLにメスアップした後、均一な状態となるまで溶解分散させ、高圧ホモジナイザーにより70MPaの均質圧で2回処理した。
(3)アルミパウチに1個あたりの重量が150gとなるよう充填し、123℃で10分間レトルト滅菌処理を行った。
(1)表2に示す組成に従い、3Lのステンレスバケツ(以下Dと記す)に調合水900gを計量し、湯浴にて70℃~80℃に加温した。
(2)TKロボミックス(プライミクス株式会社製)にて、3000rpmの高速攪拌条件下に、乳化剤である粉末レシチン(酵素分解レシチン)をDに投入した。また、食用油脂である大豆油、中鎖脂肪酸トリグリセリド、ナタネ油および精製魚油、ならびに乳化剤であるペースト状レシチン(大豆レシチン)、クエン酸モノグリセリドおよび脂肪酸モノグリセリドを、あらかじめ混合した後、Dに投入した。なお、各種食用油脂の配合量は、脂質組成において、ω-3系脂肪酸:ω-6系脂肪酸=1:2.7(重量比)となるように調整した。次いで2000mLにメスアップした後、均一な状態となるまで溶解分散させ、高圧ホモジナイザーにより70MPaの均質圧で2回処理した。
(3)アルミパウチに1個あたりの重量が150gとなるよう充填し、123℃で10分間レトルト滅菌処理を行った。
上記実施例1~4の栄養組成物について、Microlipid(ノバルティス社;登録商標)を比較例として、保存時の乳化安定性を評価した。すなわち、実施例の各栄養組成物および比較例の組成物を室温にて6ヶ月間静置保存し、乳化状態を経時的に観察した。乳化状態は以下の評価基準に従って評価し、その結果を表3に示した。
<評価基準>
○;離水およびクリーミングは認められない
△;離水もしくはクリーミングが少し認められる
×;離水もしくはクリーミングが顕著に認められる
Claims (18)
- 脂質中の中鎖脂肪酸含有量が20重量%~80重量%である脂質と、その構造中に脂肪酸を有する乳化剤を含有してなる水中油型乳化組成物であって、前記脂質および前記乳化剤の総含有量が、組成物全量に対して25(w/v)%~65(w/v)%である、栄養組成物。
- その構造中に脂肪酸を有する乳化剤が、レシチンおよび有機酸モノグリセリドよりなる群から選択した1種または2種以上である、請求項1に記載の栄養組成物。
- 有機酸モノグリセリドがクエン酸モノグリセリドである、請求項2に記載の栄養組成物。
- 脂質中の中鎖脂肪酸が、中鎖脂肪酸トリグリセリドの形態で含有されている、請求項1または2に記載の栄養組成物。
- さらに、糖類およびグリセリンよりなる群から選択した1種または2種以上を含有する、請求項1または2に記載の栄養組成物。
- 糖類およびグリセリンよりなる群から選択した1種または2種以上の含有量が、組成物全量に対して35(w/v)%以下である、請求項5に記載の栄養組成物。
- 糖尿病患者用である、請求項6に記載の栄養組成物。
- 脂質中のω-3系脂肪酸とω-6系脂肪酸の重量比が1:10~10:1である脂質を含有する、請求項1または2に記載の栄養組成物。
- リンの含有量が、栄養組成物100kcalあたり20mg以下である、請求項1または2に記載の栄養組成物。
- 腎臓病患者用である、請求項9に記載の栄養組成物。
- さらに、タンパク質、食物繊維、ビタミン類およびミネラル類よりなる群から選択される1種または2種以上を含有する、請求項1または2に記載の栄養組成物。
- 10mL~100mLの容量を一包装単位とする、請求項1または2に記載の栄養組成物。
- 無菌状態で充填されている、請求項1または2に記載の栄養組成物。
- 経口摂取用である、請求項1または2に記載の栄養組成物。
- 経胃または経腸投与用である、請求項1または2に記載の栄養組成物。
- 請求項1または2に記載の栄養組成物を含有する医薬品。
- 請求項1または2に記載の栄養組成物を含有する飲食品。
- 総合栄養組成物と、請求項1または2に記載の栄養組成物とを含む、経口摂取用または経胃もしくは経腸投与用栄養剤キット。
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012507116A JPWO2011118810A1 (ja) | 2010-03-26 | 2011-03-25 | 栄養組成物 |
| CN2011800162405A CN102811717A (zh) | 2010-03-26 | 2011-03-25 | 营养组合物 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010-073639 | 2010-03-26 | ||
| JP2010073639 | 2010-03-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2011118810A1 true WO2011118810A1 (ja) | 2011-09-29 |
Family
ID=44673350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2011/057453 Ceased WO2011118810A1 (ja) | 2010-03-26 | 2011-03-25 | 栄養組成物 |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JPWO2011118810A1 (ja) |
| CN (1) | CN102811717A (ja) |
| WO (1) | WO2011118810A1 (ja) |
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013143916A (ja) * | 2012-01-13 | 2013-07-25 | Morinaga Milk Ind Co Ltd | 腎疾患患者用の液状栄養組成物 |
| WO2013151081A1 (ja) * | 2012-04-04 | 2013-10-10 | 大正製薬株式会社 | 水性液体飲料 |
| JP2014124146A (ja) * | 2012-12-26 | 2014-07-07 | Q P Corp | 水溶性粉体成分分散高栄養組成物、及びその製造方法 |
| WO2016010008A1 (ja) * | 2014-07-16 | 2016-01-21 | 日清オイリオグループ株式会社 | 嚥下・咀嚼困難者用食品の摂食補助用油脂組成物、及び嚥下・咀嚼困難者用食品 |
| JP6012917B1 (ja) * | 2015-04-22 | 2016-10-25 | 日清オイリオグループ株式会社 | ゲル状組成物及びその製造方法 |
| JP2017093414A (ja) * | 2015-11-26 | 2017-06-01 | アイドゥ株式会社 | 微粒子乳化油脂高含有中性栄養物 |
| WO2017150325A1 (ja) * | 2016-03-03 | 2017-09-08 | 不二製油グループ本社株式会社 | 野菜ジュース |
| US9844517B2 (en) | 2010-12-29 | 2017-12-19 | Abbott Laboratories | Nutritional products including a novel fat system including fatty acids |
| CN107660793A (zh) * | 2016-07-29 | 2018-02-06 | 费森尤斯卡比德国有限公司 | 营养粉及其生产方法 |
| US9980939B2 (en) | 2013-03-13 | 2018-05-29 | Abbott Laboratories | Composition for enhancing newborn infant cognitive, brain and/or CNS development and method of using same |
| WO2018101267A1 (ja) * | 2016-11-30 | 2018-06-07 | ライオン株式会社 | 内服剤 |
| WO2018179955A1 (ja) * | 2017-03-30 | 2018-10-04 | テルモ株式会社 | 包装体 |
| WO2018179952A1 (ja) * | 2017-03-30 | 2018-10-04 | テルモ株式会社 | 高カロリー栄養組成物および包装体 |
| WO2019017006A1 (ja) * | 2017-07-21 | 2019-01-24 | テルモ株式会社 | 高カロリー栄養組成物および包装体 |
| US10328049B2 (en) | 2013-03-13 | 2019-06-25 | Abbott Laboratories | Infant nutritional product with RRR alpha-tocopherol |
| JP2022502348A (ja) * | 2018-09-21 | 2022-01-11 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | 膵外分泌不全(epi)の治療のための組成物及び方法 |
| JP2022524962A (ja) * | 2019-03-22 | 2022-05-11 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | 中鎖トリグリセリドの食前投与により食事に由来する食後血糖を低減する方法 |
| WO2022270369A1 (ja) * | 2021-06-24 | 2022-12-29 | 森永乳業株式会社 | 栄養組成物 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108208839A (zh) * | 2016-12-22 | 2018-06-29 | 费森尤斯卡比德国有限公司 | 包含脂质的高热量液体营养乳剂 |
| CN108208798A (zh) * | 2017-12-29 | 2018-06-29 | 北京康爱营养科技股份有限公司 | 全营养配方液及其制备方法 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2935573A1 (de) * | 1979-09-03 | 1981-03-19 | Lepharm- Pharmazeutische Entwicklungs- und Vertriebsgesellschaft GmbH, 5000 Köln | Infusionsloesungen mit mono- und diglyceriden von fettsaeuren |
| JPS63296663A (ja) * | 1987-05-28 | 1988-12-02 | Nisshin Oil Mills Ltd:The | 治療用食品 |
| EP0510687A2 (en) * | 1991-04-26 | 1992-10-28 | The Green Cross Corporation | Infusion preparation |
| EP0691079A2 (en) * | 1994-07-06 | 1996-01-10 | Clintec Nutrition Company, An Illinois Partnership | Enteral composition for diabetic patients |
| JPH09157179A (ja) * | 1995-12-04 | 1997-06-17 | Terumo Corp | 液状栄養組成物 |
| CN101244037A (zh) * | 2007-02-12 | 2008-08-20 | 广州富邦医药科技有限公司 | 一种注射用高浓度中/长链脂肪乳注射液及其制造方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61135572A (ja) * | 1984-12-07 | 1986-06-23 | Nippon Oil & Fats Co Ltd | 経腸用脂肪乳剤 |
| JP2950348B2 (ja) * | 1991-04-27 | 1999-09-20 | 吉富製薬株式会社 | 脂肪乳剤及びその製造法 |
| JP4925458B2 (ja) * | 2007-12-13 | 2012-04-25 | 日清オイリオグループ株式会社 | クリーム用油脂組成物及び該油脂組成物を含有するクリーム |
-
2011
- 2011-03-25 CN CN2011800162405A patent/CN102811717A/zh active Pending
- 2011-03-25 WO PCT/JP2011/057453 patent/WO2011118810A1/ja not_active Ceased
- 2011-03-25 JP JP2012507116A patent/JPWO2011118810A1/ja active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2935573A1 (de) * | 1979-09-03 | 1981-03-19 | Lepharm- Pharmazeutische Entwicklungs- und Vertriebsgesellschaft GmbH, 5000 Köln | Infusionsloesungen mit mono- und diglyceriden von fettsaeuren |
| JPS63296663A (ja) * | 1987-05-28 | 1988-12-02 | Nisshin Oil Mills Ltd:The | 治療用食品 |
| EP0510687A2 (en) * | 1991-04-26 | 1992-10-28 | The Green Cross Corporation | Infusion preparation |
| EP0691079A2 (en) * | 1994-07-06 | 1996-01-10 | Clintec Nutrition Company, An Illinois Partnership | Enteral composition for diabetic patients |
| JPH09157179A (ja) * | 1995-12-04 | 1997-06-17 | Terumo Corp | 液状栄養組成物 |
| CN101244037A (zh) * | 2007-02-12 | 2008-08-20 | 广州富邦医药科技有限公司 | 一种注射用高浓度中/长链脂肪乳注射液及其制造方法 |
Cited By (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9844517B2 (en) | 2010-12-29 | 2017-12-19 | Abbott Laboratories | Nutritional products including a novel fat system including fatty acids |
| JP2013143916A (ja) * | 2012-01-13 | 2013-07-25 | Morinaga Milk Ind Co Ltd | 腎疾患患者用の液状栄養組成物 |
| JPWO2013151081A1 (ja) * | 2012-04-04 | 2015-12-17 | 大正製薬株式会社 | 水性液体飲料 |
| WO2013151081A1 (ja) * | 2012-04-04 | 2013-10-10 | 大正製薬株式会社 | 水性液体飲料 |
| JP2014124146A (ja) * | 2012-12-26 | 2014-07-07 | Q P Corp | 水溶性粉体成分分散高栄養組成物、及びその製造方法 |
| US9980939B2 (en) | 2013-03-13 | 2018-05-29 | Abbott Laboratories | Composition for enhancing newborn infant cognitive, brain and/or CNS development and method of using same |
| US10328049B2 (en) | 2013-03-13 | 2019-06-25 | Abbott Laboratories | Infant nutritional product with RRR alpha-tocopherol |
| US10702496B2 (en) | 2013-03-13 | 2020-07-07 | Abbott Laboratories | Method of using a composition for enhancing newborn infant cognitive, brain and/or CNS development |
| WO2016010008A1 (ja) * | 2014-07-16 | 2016-01-21 | 日清オイリオグループ株式会社 | 嚥下・咀嚼困難者用食品の摂食補助用油脂組成物、及び嚥下・咀嚼困難者用食品 |
| JP6012917B1 (ja) * | 2015-04-22 | 2016-10-25 | 日清オイリオグループ株式会社 | ゲル状組成物及びその製造方法 |
| WO2016170939A1 (ja) * | 2015-04-22 | 2016-10-27 | 日清オイリオグループ株式会社 | ゲル状組成物及びその製造方法 |
| KR101812462B1 (ko) | 2015-04-22 | 2017-12-26 | 닛신 오일리오그룹 가부시키가이샤 | 겔상 조성물 및 그의 제조 방법 |
| JP2017093414A (ja) * | 2015-11-26 | 2017-06-01 | アイドゥ株式会社 | 微粒子乳化油脂高含有中性栄養物 |
| WO2017150325A1 (ja) * | 2016-03-03 | 2017-09-08 | 不二製油グループ本社株式会社 | 野菜ジュース |
| JPWO2017150325A1 (ja) * | 2016-03-03 | 2018-03-08 | 不二製油株式会社 | 野菜ジュース |
| CN107660793A (zh) * | 2016-07-29 | 2018-02-06 | 费森尤斯卡比德国有限公司 | 营养粉及其生产方法 |
| WO2018101267A1 (ja) * | 2016-11-30 | 2018-06-07 | ライオン株式会社 | 内服剤 |
| JP7061574B2 (ja) | 2016-11-30 | 2022-04-28 | ライオン株式会社 | 内服剤 |
| JPWO2018101267A1 (ja) * | 2016-11-30 | 2019-10-24 | ライオン株式会社 | 内服剤 |
| WO2018179952A1 (ja) * | 2017-03-30 | 2018-10-04 | テルモ株式会社 | 高カロリー栄養組成物および包装体 |
| JPWO2018179952A1 (ja) * | 2017-03-30 | 2020-02-06 | テルモ株式会社 | 高カロリー栄養組成物および包装体 |
| JPWO2018179955A1 (ja) * | 2017-03-30 | 2020-02-06 | テルモ株式会社 | 包装体 |
| WO2018179955A1 (ja) * | 2017-03-30 | 2018-10-04 | テルモ株式会社 | 包装体 |
| WO2019017006A1 (ja) * | 2017-07-21 | 2019-01-24 | テルモ株式会社 | 高カロリー栄養組成物および包装体 |
| JPWO2019017006A1 (ja) * | 2017-07-21 | 2020-08-20 | テルモ株式会社 | 高カロリー栄養組成物および包装体 |
| JP7084926B2 (ja) | 2017-07-21 | 2022-06-15 | テルモ株式会社 | 高カロリー栄養組成物および包装体 |
| JP2022502348A (ja) * | 2018-09-21 | 2022-01-11 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | 膵外分泌不全(epi)の治療のための組成物及び方法 |
| JP7506658B2 (ja) | 2018-09-21 | 2024-06-26 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | 膵外分泌不全(epi)の治療のための栄養組成物 |
| US12433316B2 (en) | 2018-09-21 | 2025-10-07 | Societe Des Produits Nestle S.A. | Compositions and methods for treatment of exocrine pancreatic insufficiency (EPI) |
| JP2022524962A (ja) * | 2019-03-22 | 2022-05-11 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | 中鎖トリグリセリドの食前投与により食事に由来する食後血糖を低減する方法 |
| JP7498723B2 (ja) | 2019-03-22 | 2024-06-12 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | 中鎖トリグリセリドの食前投与により食事に由来する食後血糖を低減する組成物 |
| WO2022270369A1 (ja) * | 2021-06-24 | 2022-12-29 | 森永乳業株式会社 | 栄養組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102811717A (zh) | 2012-12-05 |
| JPWO2011118810A1 (ja) | 2013-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2011118810A1 (ja) | 栄養組成物 | |
| DK2658405T3 (en) | Food products comprising a fat system, including free fatty acids | |
| JP2014003960A (ja) | 液状栄養組成物 | |
| WO2013146181A1 (ja) | 乳化食品組成物 | |
| JP7165583B2 (ja) | コラーゲンを含む高カロリー、高タンパク質の栄養配合物 | |
| KR20120104382A (ko) | 액상 식품 조성물 | |
| JP2007126379A (ja) | 酸性液状経腸栄養剤の製造方法 | |
| JP5902815B2 (ja) | 酸性液状栄養剤 | |
| KR102069931B1 (ko) | 액상 영양 조성물 | |
| CN112891304B (zh) | 一种高能量密度的脂肪乳剂及其制备方法和其应用 | |
| TW201234981A (en) | Compositions and methods for nutrient delivery | |
| JP2014024819A (ja) | 乳化状栄養組成物 | |
| US12096785B2 (en) | Lipid emulsion nutritional product | |
| JPS6342510B2 (ja) | ||
| JP7524490B2 (ja) | 液状栄養組成物および包装体 | |
| JPH03117472A (ja) | 投与バツグ式流動食 | |
| JPWO2013125067A1 (ja) | 胃瘻用半固形栄養剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 201180016240.5 Country of ref document: CN |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11759614 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2012507116 Country of ref document: JP |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 11759614 Country of ref document: EP Kind code of ref document: A1 |